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Edited by Laszlo NagyAbstract In this study, we examined the eﬀects of intracerebro-
ventricular administration of melanotan II (MTII), a melanocor-
tin agonist, on insulin sensitivity in diet-induced obese (DIO)
rats. Although MTII treatment signiﬁcantly decreased food in-
take and body weight for 10 days, there was no signiﬁcant diﬀer-
ence in body weight between MTII and pair-fed groups. The
insulin tolerance test showed that insulin sensitivity was signiﬁ-
cantly improved in the MTII group compared to the pair-fed
group. Furthermore, MTII treatment increased the number of
small-sized adipocytes in epididymal white adipose tissues, sug-
gesting that MTII increased insulin sensitivity through action
on the white adipose tissues in DIO rats.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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activated receptor c1. Introduction
The consumption of a high caloric diet is one of the main
causes of obesity [1]. Rats fed with a high fat diet show in-
creases in body weight and decreases in insulin sensitivity [2],
and these diet-induced obese (DIO) rats have been used for
studying the mechanisms of insulin resistance due to obesity.
It has been demonstrated that the size and weight of adipose
tissues are increased in DIO rats [3], and that the hypertrophy
of adipocytes leads to changes in the release of adipocytokines
such as leptin and adiponectin regulating insulin sensitivity
[4,5]. These morphological changes in adipose tissues as well
as changes in plasma levels of adipocytokines have been postu-Abbreviations: MTII, melanotan II; DIO, diet-induced obesity; PO-
MC, pro-opiomelanocortin; icv, intracerebroventricular; ITT, insulin
tolerance tests; TG, triglyceride; WAT, white adipose tissue; BAT,
brown adipose tissue; PPARc, peroxisome proliferator-activated rec-
eptor c; aP-2, adipocyte-speciﬁc fatty acid binding protein; qRT-PCR,
real-time quantitative RT-PCR; SNS, sympathetic nervous systems
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[6,7].
The melanocortin systems in the hypothalamus, including a
subset of neurons in the arcuate nucleus synthesizing pro-opi-
omelanocortin (POMC), are one of the key systems in energy
homeostasis [8]. POMC neurons in the arcuate nucleus are
inﬂuenced by humoral factors such as leptin synthesized in adi-
pose tissues as well as neural inputs reﬂecting energy balance
[9], and melanocortins cleaved from POMC exert their eﬀects
by binding to members of a family of melanocortin receptors
in the brain [10]. While the major action of melanocortin in
the brain is to reduce food intake, it is also demonstrated that
melanocortin agonists or antagonists injected into the cerebral
ventricle aﬀected insulin actions in the periphery while food
was withdrawn or the intake was maintained constant
[11,12]. These data suggest that the action of melanocortin
on insulin sensitivity is, at least partially, independent of en-
ergy balance, although the detailed mechanisms have not been
fully elucidated.
In the present study, we examined the eﬀects of the activa-
tion of central melanocortin pathways on insulin sensitivity,
morphological changes in adipocytes and serum levels of adio-
cytokines in DIO rats.2. Materials and methods
2.1. Animals and treatment
Male Sprague–Dawley rats (age 7 weeks, body weight 200–225 g;
Chubu Science Materials, Nagoya, Japan) were housed in individual
cages at 23 C with lights on from 0900 to 2100 h. Rats fed a high-
fat diet (60.1% energy as fat and 15.6% as carbohydrate) for 12 weeks
were anesthetized by an intraperitoneal (i.p.) injection of sodium pen-
tobarbital (50 mg/kg BW), and a 28-gauge stainless steel cannula
(Brain infusion kit II; Alzet, Palo Alto, CA) was inserted stereotaxi-
cally into the right lateralventricle for an intracerebroventricular
(icv) injection. An osmotic mini-pump (Model 2002; Alzet, Palo Alto,
CA) connected to the cannula was placed subcutaneously. Vehicle
(0.9% saline) was constantly administered into the right lateral ventri-
cle for 2 weeks through icv cannula connected osmotic mini-pumps.
After these 2-week recovery periods, on day 0, all rats were anesthe-
tized again with diethyl ether for subcutaneous replacement of another
osmotic mini-pump containing vehicle or melanotan II (MTII) (kindly
provided by Sankyo Corporation, Tokyo, Japan) dissolved in vehicle.
Vehicle or MTII (1 lg/day) was administered constantly into the lat-
eral ventricle for 10 days through the replaced osmotic mini-pumps,
and food intake and body weight of the animals were measured daily.blished by Elsevier B.V. All rights reserved.
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guidelines for animal care of the Nagoya University Graduate School
of Medicine.2.2. Food intake and body weight measurements
The food intake and body weight of DIO rats were measured daily
between 1900 and 2100 h. DIO rats were divided into three groups: (1)
ad libitum group, with a mini-pump containing vehicle and allowed to
eat 0 ad libitum; (2) MTII group, with a mini-pump containing MTII
and free access to food; and (3) pair-fed group, with a mini-pump con-
taining vehicle and pair-fed the same amount of food as those in the
MTII group. All groups were fed a high-fat diet throughout the exper-
iments.2.3. Insulin tolerance test (ITT)
On day 7, ITT was performed between 0900 h and 1200 h on animals
fasted for 10 h before the test. To minimize the duration of fast in pair-
fed group, the matched amount of food was served to the pair-fed
group at 1900 h as well as at 3 h before food was withdrawn on day
6. Human regular insulin (1 U/kg body weight: humalin R; Eli Lilly Ja-
pan, Kobe, Japan) was administered intraperitoneally, and blood sam-
ples were taken from the tail vein of the conscious rats before and 30,
60, 90 and 120 min after insulin administration. Blood glucose levels
were immediately measured with a blood glucose monitor (TERUMO
Corporation, Tokyo, Japan).2.4. Fat pad and tissue analysis
On day 10 all rats were decapitated between 0900 h and 1200 h. Rats
in MTII and ad libitum groups had free access to food until sacriﬁce
while those in the pair-fed group were served the matched amount of
food 3 h before sacriﬁce. After sacriﬁcing by decapitation, the epidid-
ymal, perirenal, retroperitoneal and inguinal subcutaneous white adi-
pose tissue (WAT) and interscapular brown adipose tissue (BAT) as
well as liver were dissected out. The epididymal WAT and liver were
immediately frozen in liquid nitrogen and stored at 80 C for future
measurement. One part of the epididymal WAT was immersed in 4%
buﬀered formaldehyde until future analysis.2.5. Serum adiponectin and leptin measurement
Serum leptin and adiponectin levels were measured with enzyme-
linked immunosorbent assay commercial kits (Wako, Osaka, Japan,
and Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan, respectively).2.6. Triglyceride (TG) content in liver
One hundred milligram frozen sections of liver were homogenized,
and tissue lipids were extracted with an extract solution (chloro-
form:methanol = 2:1), and then solubilized in isopropanol after sam-
ples were dried. TG content levels measured with an enzymatic
commercial kit (Wako).Fig. 1. Changes in daily food intake (A) and body weight (B) of DIO
rats. DIO rats were divided into three groups: ad libitum (closed
circles), pair-fed (triangles) and MTII (closed squares) groups. ,
P < 0.05 MTII vs ad libitum; §, P < 0.05 pair-fed vs ad libitum.2.7. Determination of DNA content and mRNA levels by real-time PCR
The genomic DNA was extracted and puriﬁed from a piece of 25 mg
frozen epididymal WAT using NucleoSpin Tissue kit (NIPPON
Genetics Co., Ltd., Tokyo, Japan). The DNA content of WAT was
measured by spectrophotometer method using NanoDrop ND-1000
(Nanodrop Technologies, Wilmington, DE, USA). The mRNA levels
of peroxisome proliferator-activated receptor c (PPARc), adipocyte-
speciﬁc fatty acid binding protein (aP-2) and 36B4 were assessed and
quantiﬁed by real-time quantitative RT-PCR (qRT-PCR). Total
RNA was extracted from 100 mg frozen epididymal WAT with the
Trizol reagents (Invitrogen Corporation, Carlsbad, CA, USA), and
cDNAs were synthesized from 1 lg total RNA using SuperScript II
reverse transcriptase (Invitrogen Japan K.K.). The qRT-PCR was
carried out in a 20 ll reaction mixture that contained 2 ll of the
above cDNA products and SYBR Green I PCR Matrix (Eurogentec,
Seraing, Belgium). The levels of PPARc and aP-2 mRNA were
normalized to that of 36B4. The sequence primers were: PPARc
forward 5 0-CATGACCAGGGAGTTCCTCAA, reverse 5 0-AGCA-
AACTCAAACTTAGGCTC- CAT; aP-2 forward 5 0-GAGTTGG-
CTTCGCCACCA, reverse 5 0-AAGTCCCCTTCTA-CGCTGATGA;
36B4 forward 5 0-CCTTCCCACTG-GCTGAAAAG, reverse 5 0-CG-
CAGCCGCAAATGC.2.8. Histological analysis and morphometry
Epididymal WATs ﬁxed in 4% formaldehyde were embedded in par-
aﬃn, cut at a thickness of 10 lm on a microtome, placed on slides, and
stained with hematoxylin and eosin. For the quantiﬁcation of the num-
ber and size of adipocytes, the sectional areas of epididymal adipocytes
(160000 lm2per each rat) were traced manually and analyzed with an
image analysis system (NEUROLUCIDA software; MicroBright-
Field Japan, Inc., Japan). The numbers of adipocytes of each size from
eight rats in each group were shown as histograms.
2.9. Statistical analyses
All results are expressed as mean values ± S.E.M. Data were ana-
lyzed by one-way (treatment) or two-way (treatment, time) ANOVA.
For time course changes in body weight and food intake, repeated
measures ANOVA were employed. These analyses were followed by
a Fisher protected least signiﬁcant diﬀerence test for post hoc compar-
isons. Diﬀerences were considered statistically signiﬁcant at P < 0.05.
The group size was eight in all experiments.3. Results
3.1. Eﬀect of MTII administration on food intake and body
weight
Repeated ANOVA revealed that there was a signiﬁcant
treatment eﬀect on daily food intake [F(1,14) = 17.4,
P < 0.01]. The post hoc analyses revealed that daily food in-
take in the MTII group was signiﬁcantly lower compared to
the ad libitum group throughout the experiment (Fig. 1A).
There was also a signiﬁcant treatment eﬀect on body weight
[F(2,21) = 20.1, P < 0.01]. However, post hoc analyses re-
vealed that, although body weight in MTII and pair-fed
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group, there were no signiﬁcant diﬀerences in changes in body
weight between MTII and pair-fed groups (Fig. 1B).3.2. Eﬀect of MTII administration on ITT
There were no signiﬁcant diﬀerences in blood glucose levels
before insulin injection between the groups (ad libitum 105.8 ±
15.8 mg/dl, pair-fed 95.9 ± l5.5 mg/dl, MTII 96.2 ± 5.9 mg/dl).
Two-way ANOVA revealed a signiﬁcant treatment eﬀect
[F(2,105) = 87.0, P < 0.01], time eﬀect [F(4,105) = 328.4, P <
0.01] and treatment-time interaction [F(8,105) = 5.59, P <
0.01]. The post hoc analyses revealed that changes in blood
glucose levels after insulin injection were signiﬁcantly lower
in MTII group than in the ad libitum and pair-fed groups at
all time points examined, and that the values in pair-fed groups
were signiﬁcantly lower than in ad libitum groups at 60, 90 and
120 min (Fig. 2).3.3. Eﬀect of MTII administration on fat pad and TG content in
liver
There were no signiﬁcant diﬀerences among ad libitum, pair-
fed and MTII groups in the weight of visceral WAT (sum of
epididymal, perirenal and retroperitoneal fat, Fig. 3A), subcu-
taneous WAT (Fig. 3B) or BAT (Fig. 3C). On the other hand,
there was a signiﬁcant treatment eﬀect on TG contents in liver
[F(2,21) = 5.00, P < 0.01]. The post hoc analyses revealed that
the TG contents in liver were signiﬁcantly decreased in MTII
group compared to other groups (Fig. 3D).3.4. Eﬀect of MTII administration on adipocytes in epididymal
WAT
Histological analysis revealed that MTII treatment increased
the population of smaller-sized adipocytes in epididymal WAT
of DIO rats (Fig. 4). There was a signiﬁcant treatment eﬀect on
the DNA content in epididymal WAT [F(2,21) = 8.08,Fig. 2. Intraperitoneal insulin tolerance test in DIO rats on day 7. DIO
rats were divided into three groups: ad libitum (closed circles), pair-fed
(triangles) and MTII (closed squares) groups. After being fasted for
10 h, rats were injected with human regular insulin (1.0 U/kg body
weight) intraperitoneally, and blood glucose levels were measured.
Levels relative to initial values were shown. , P < 0.05 MTII vs
ad libitum; *, P < 0.05 MTII vs pair-fed; §, P < 0.05 pair-fed vs
ad libitum.
Fig. 3. Eﬀects of icv infusion of MTII on adipose weight (A–C) and
TG content in liver (D) in DIO rats. Visceral WAT weight is sum of
epididymal, perirenal and retroperitoneal fat weight, while subcutane-
ous WAT is from inguinal subcutaneous fat. , P < 0.05 MTII vs
ad libitum; *, P < 0.05 MTII vs pair-fed.P < 0.01], and the post hoc analyses revealed that the DNA
content was signiﬁcantly increased in the MTII group com-
pared to the ad libitum and pair-fed groups, whereas there
were no signiﬁcant diﬀerences in the DNA content between
the pair-fed and ad libitum groups (Fig. 5A).
3.5. Eﬀect of MTII administration on gene expressions in
epididymal WAT
There were signiﬁcant treatment eﬀects on the expression
levels of PPARc mRNA [F(2,21) = 35.7, P < 0.01] and aP-2
[F(2,21) = 20.2, P < 0.01]. The post hoc analyses revealed that
the expression levels of PPARc mRNA as well as aP-2 were
signiﬁcantly higher in the MTII group compared to the ad libi-
tum and pair-fed groups, whereas there were no signiﬁcant dif-
ferences in the levels between the ad libitum and pair-fed
groups (Fig. 5B and C).
Fig. 4. Histology of epididymal WAT and quantiﬁcation of cell sizes and numbers in ad libitum (A,B), pair-fed (C,D) and MTII (E,F) groups. Black
bars in panels indicate 100 lm. Sectional areas (160000 lm2 per rat) were analyzed with an image analysis system, and numbers of adipocytes of each
size from eight rats in each group were shown as histograms (B,D,F).
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There were signiﬁcant treatment eﬀects on the serum levels
of adiponectin [F(2,21) = 35.4, P < 0.01] and leptin
[F(2,21) = 7.48, P < 0.01]. The post hoc analyses revealed that
the serum adiponectin levels in the MTII group were signiﬁ-
cantly higher compared to either ad libitum or pair-fed groups,
while there were no signiﬁcant diﬀerences in the levels between
ad libitum and pair-fed groups (Fig. 6A). On the other hand,
the serum leptin levels in MTII group were signiﬁcantly higher
compared to the pair-fed group, while the levels in the pair-fed
group were signiﬁcantly lower compared to the ad libitum
group (Fig. 6B).4. Discussion
It has been shown that the activation or blockade of central
MC4R pathways aﬀected insulin sensitivity in the peripheryvia mechanisms other than changing the energy balance
[11,12]. Our data demonstrated, for the ﬁrst time to our knowl-
edge, that the activation of central MC4R pathways could also
ameliorate insulin resistance induced by a high-fat diet and
that the action was independent of energy balance. As the size
of adipocytes in WAT, which is closely related to insulin sen-
sitivity in adipose tissues [7], was decreased by MTII treat-
ment, it is suggested that the melanocortin systems increased
insulin sensitivity at the level of WAT in DIO rats, at least
to some degree. Our data also demonstrated that TG content
in liver was signiﬁcantly decreased by MTII treatment. To-
gether with a previous study showing that chronic administra-
tion of a-MSH increased tyrosine phosphorylation of insulin
receptor substrate-1, 2 in liver in rats [12], it is suggested that
activation of central melanocortin systems leads to increases
in insulin sensitivity at the level of liver as well. Furthermore,
it is reported that an acute injection of MTII increased
GLUT4 mRNA expression in skeletal muscle in mice [11].
Fig. 5. DNA content (A) and gene expression of PPARc (B) and aP-2
(C) in epididymal WAT of ad libitum (Ad lib.), pair-fed (P-fed) and
MTII groups. , P < 0.05 MTII vs ad libitum; *, P < 0.05 MTII vs
pair-fed.
Fig. 6. Serum levels of adiponectin (A) and leptin (B) in ad libitum
(Ad lib.), pair-fed (P-fed) and MTII groups. , P < 0.05 MTII vs
ad libitum; *, P < 0.05 MTII vs pair-fed; §, P < 0.05 pair-fed vs
ad libitum.
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melanocortin systems on the regulation of insulin sensitivity in
the periphery could be diverse.
Our data showed that MTII treatment signiﬁcantly in-
creased the PPARc gene expression, which is upregulated
when adipocytes are proliferated and diﬀerentiated [13]. This
was further conﬁrmed by signiﬁcant increases in aP-2, which
is shown to be downstream of PPARc in WAT [14]. Together
with the signiﬁcant increase in DNA content in the epididymal
WAT, our results suggest that the total number of adipocytes
in the epididymal WAT was increased by MTII treatment.
Although the regulation of the diﬀerentiation and proliferation
of adipocytes has not been fully elucidated, there is evidence
that the stimulation of melanocortin receptors activated the
sympathetic nervous system (SNS) [15], which innervatesWAT [16]. Thus, it is possible that MTII increased the number
of small-sized adipocytes by inducing cell proliferation and dif-
ferentiation in WAT through SNS, although further studies
are necessary to prove this.
Adiponectin synthesized in and secreted from adipose tissues
increases insulin sensitivity through its receptors in liver and
muscle [17,18]. It is reported that the plasma levels of adipo-
nectin were decreased in DIO rats, and that administration
of adiponectin improved their insulin resistance [18]. Decreases
in plasma adiponectin levels are also reported in obese patients
and thus have been postulated as one of the possible causes of
insulin resistance in metabolic syndrome [19]. In the present
study, MTII treatment signiﬁcantly increased the release of
adiponectin in DIO rats. These changes could be due to de-
creases in the size of adipocytes [4], and possibly contributed,
at least partially, to the improvement in insulin sensitivity in-
duced by MTII.
Leptin is also one of the adipocytokines whose role in energy
balance has been extensively studied [20–22]. Leptin decreases
food intake and increases energy expenditure through its
receptors in the hypothalamus [20,21], and central melanocor-
tin systems are, to some extent, involved in leptin action [8,21].
In contrast to adiponectin, plasma levels of leptin as well as its
synthesis in WAT increase in parallel with adipose stores [5].
Plasma leptin levels were increased in DIO rats as well as in
obese patients [2,22,23], results that have been interpreted as
leptin resistance. In the present study, while the size of adipo-
cytes in WAT was signiﬁcantly decreased, serum levels of lep-
tin were signiﬁcantly increased by MTII treatment, suggesting
that MTII stimulated leptin release via mechanisms indepen-
1136 R. Banno et al. / FEBS Letters 581 (2007) 1131–1136dent of morphological changes in WAT. Thus, our data sug-
gest that melanocortin systems are not only downstream of
leptin but also could regulate leptin release. Elucidation of
the detailed mechanisms of mutual regulation between central
melanocortin systems and adipose tissues is an important task
for future study.
In conclusion, we demonstrated that activation of the central
melanocortin systems increased insulin sensitivity through its
action on the white adipose tissues in DIO rats.
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